S
3.84
-0.08 (-2.04%)
| Penutupan Terdahulu | 3.92 |
| Buka | 3.96 |
| Jumlah Dagangan | 454,915 |
| Purata Dagangan (3B) | 395,525 |
| Modal Pasaran | 202,721,280 |
| Harga / Jualan (P/S) | 5.84 |
| Harga / Buku (P/B) | 28.45 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Aug 2025 - 18 Aug 2025 |
| Margin Keuntungan | -216.24% |
| Margin Operasi (TTM) | -151.10% |
| EPS Cair (TTM) | -1.92 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 92.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 395.59% |
| Nisbah Semasa (MRQ) | 5.48 |
| Aliran Tunai Operasi (OCF TTM) | -69.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -46.02 M |
| Pulangan Atas Aset (ROA TTM) | -49.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -934.02% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | scPharmaceuticals Inc. | Menurun | Menurun |
AISkor Stockmoo
-0.3
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.25 |
|
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.08% |
| % Dimiliki oleh Institusi | 77.72% |
| Julat 52 Minggu | ||
| Median | 6.00 (56.25%) | |
| Jumlah | 1 Pegang | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Craig-Hallum | 26 Aug 2025 | 6.00 (56.25%) | Pegang | 5.53 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Aug 2025 | Pengumuman | MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases |
| 14 Aug 2025 | Pengumuman | scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111 |
| 07 Aug 2025 | Pengumuman | scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update |
| 31 Jul 2025 | Pengumuman | scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |